Ra Pharmaceuticals (RARX) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Ra Pharmaceuticals (NASDAQ:RARX) announced its quarterly earnings data on Wednesday. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.02), Fidelity Earnings reports.

Shares of NASDAQ:RARX traded down $0.31 during midday trading on Friday, hitting $12.01. 13,028 shares of the company’s stock were exchanged, compared to its average volume of 241,270. The company has a market cap of $446.62 million, a PE ratio of -4.98 and a beta of 2.08. Ra Pharmaceuticals has a 12 month low of $4.78 and a 12 month high of $19.43.

Several equities analysts have recently weighed in on the stock. ValuEngine lowered shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 16th. BMO Capital Markets set a $21.00 price objective on shares of Ra Pharmaceuticals and gave the company a “buy” rating in a report on Thursday. BidaskClub upgraded shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 19th. Zacks Investment Research upgraded shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Tuesday, August 14th. Finally, Credit Suisse Group set a $25.00 price objective on shares of Ra Pharmaceuticals and gave the company a “buy” rating in a report on Friday, October 19th. Three investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Ra Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $20.80.

TRADEMARK VIOLATION NOTICE: “Ra Pharmaceuticals (RARX) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://sportsperspectives.com/2018/11/09/ra-pharmaceuticals-rarx-posts-quarterly-earnings-results-misses-estimates-by-0-02-eps.html.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Article: NASDAQ

Earnings History for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply